The Children’s Oncology Group (COG) is the most experienced organization in the world in clinical development of new therapeutics for children and adolescents with cancer.
The Children’s Oncology Group Phase 1 & Pilot Consortium is a limited institution consortium, comprised of 21 premier pediatric oncology programs in the country that were selected through a peer review process. Formed in 2002, the primary goals of the consortium are to identify and develop effective new agents for children and adolescents with cancer through rational and efficient clinical and laboratory research. The consortium serves as a national and international model for new drug development in pediatric oncology.
The consortium successfully leverages the database infrastructure and resources of the parent Children’s Oncology Group (COG) while maintaining its own administrative and operational infrastructure to ensure rapid development, implementation and reporting of specialized and complex early phase clinical trials. The consortium has expert resources for the conduct of translational biology, pharmacokinetic, and pharmacogenetics studies, and has developed a state-of-the art infrastructure to facilitate image transfer of specialized correlative imaging studies for central review and analyses.
COG Operations Center
The primary mission of the COG Phase I & Pilot Consortium is to identify and develop effective new agents for children and adolescents with cancer through rational and efficient clinical and laboratory research.
COG Phase 1 Consortium grant, supporting 21 premier COG institutions charged with early phase clinical trials, is primarily funded by the National Cancer Institute and also receives additional funding from other granting agencies and from philanthropic sources (http://cog-foundation.org ).